SI
SI
discoversearch

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor.  We ask that you disable ad blocking while on Silicon Investor in the best interests of our community.  If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.
Biotech / Medical
MAXM: Maxim Pharmaceuticals
An SI Board Since November 2000
Posts SubjectMarks Bans Symbol
35 8 0 MAXM
Emcee:  SI (no user) Type:  Unmoderated
Introduction Market Data Compact
This message board is intended for discussion of MAXM: Maxim Pharmaceuticals.
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
ReplyMessage PreviewFromRecsPosted
35llcalgal-8/3/2012
34EpiCept Announces Publication of Phase III Ceplene(TM) Study Results for Acute MIcebrg-3/31/2006
33>>Mol Cancer Ther. 2004;3:1365-1374 Discovery and mechanism of action of tuck-12/2/2004
32Maxim Pharmaceuticals (MAXM-NNM) by Brean Murray (7, Aug. 25) We are maintainingmopgcw-8/29/2004
31Ohhhh. Thanks, Ice. Now I get it.keokalani'nui-5/12/2004
30>>What does ceplene w/IL-2 vs nothing tell us about their drug?>> NIcebrg-5/12/2004
29I don't get it, but then I haven't followed these guys for years. Whatkeokalani'nui-5/12/2004
28Maxim Pharmaceuticals Announces Phase 3 Trial of Ceplene in Acute Myeloid Leukemnigel bates-5/12/2004
27Maxim Pharmaceuticals Discovers Potential Therapeutic Against the SARS Coronavirkeokalani'nui-1/22/2004
26Maxim Files for European Approval to Market Ceplene for the Treatment of Advancenigel bates-11/7/2003
25Maxim Pharmaceuticals Announces Publication of Ceplene Phase 3 Quality of Life Rnigel bates-6/12/2003
24Cytovia shareholders eagerly sold out to Maxim Pharmaceuticals in 2000. But MaxiIcebrg-4/23/2003
23Maxim Pharmaceuticals Receives Phase 2 SBIR Grant from National Cancer InstituteSemiBull-3/13/2003
22Maxim Announces Results of Preclinical Research Suggesting Ceplene Accelerates RIcebrg-11/4/2002
21Maxim Advances Enrollment of Ceplene Phase 2 Clinical Trial in Hepatitis C NonreSemiBull-9/10/2002
20Maxim Announces Initiation of Enrollment in Oral Mucositis Clinical Study SAN DSemiBull-8/19/2002
19Maxim Pharmaceuticals Announces 2002 Third Quarter Financial Results SAN DIEGO-SemiBull-8/1/2002
18Maxim Receives Three Additional U.S. Patents for Ceplene Immune Modulator TechnoSemiBull-7/16/2002
17Maxim's Ceplene Featured in Six Articles in Seminars in Oncology Supplement SemiBull-7/8/2002
16An Open Letter to the Biotech Industry... It's pretty clear that the SThe Fox-6/16/2002
15Maxim Announces Results From Phase 2 Clinical Study of Ceplene in the Treatment SemiBull-5/22/2002
14Maxim Announces Preclinical Research Suggesting Ceplene May Prevent Liver DamageSemiBull-5/21/2002
13Maxim's Apoptosis Inhibitor Protects Against Kidney Ischemia/Reperfusion InjSemiBull-5/6/2002
12Maxim Pharmaceuticals Announces 2002 Second Quarter Financial Results SAN DIEGO-SemiBull-5/2/2002
11Maxim's Ceplene Improves Human Immune Cell Activation by Interferon-Alpha inSemiBull-4/22/2002
Previous 25 | Next 25 | View Recent | Post Message
Go to reply# or date (mm/dd/yy):
HomeMailHotSubjectMarksPeopleMarksKeepersSettings
Terms Of UseContact UsCopyright/IP PolicyPrivacy PolicyAbout UsFAQAdvertise on SI
© 2025 Knight Sac Media.  Data provided by Twelve Data, Alpha Vantage, and CityFALCON News